· Health Care Technology · S&P SmallCap 600
CERT CERTARA $1.3B
No. Drafting and faster modeling are one assist. The scientist still decides.
5 of 15
Reach, Weight, and Proof.
What they are doing
Certara's annual report for the year ended 31 December 2025, filed 26 February 2026, says machine learning speeds biosimulation, including model choice in Pirana and an AI module for pharmacokinetic reports in Phoenix. Certara.AI, launched in 2023, is a set of life-sciences language models for search and drafting. CoAuthor, launched in 2024, uses generative AI to draft regulatory documents. The report says a scientist stays in the loop and the validated model still supports the decision. No time saved and no approval figure is given. The quarterly report for the period ended 30 June 2026 repeats that approach and does not add a result. The August earnings release does not name these products.
Why the score
- Reach 1 not 0: biosimulation and document drafting are named.
- Reach 1 not 2: they are one scientific assist, not two operating functions.
- Weight 2 not 3: faster modeling and faster drafting. The filing says the expert still decides.
- Proof 2 not 3: the products are named. Nothing shows them running with a result.
What would move it next quarter: A result on a dose decision or a submission, after the model was in use. Another drafting feature will not move this.
Open these first
Evidence
Machine learning speeds biosimulation and model selection. Certara.AI, launched in 2023, deploys life-sciences language models for search and drafting. CoAuthor, launched in 2024, uses generative AI to draft regulatory documents. The company says scientists stay in the loop and validated models still support the decision. No cycle time and no approval figure are given.
The quarter says machine learning is used to speed biosimulation, inside expert-led workflows. It does not name CoAuthor or Certara.AI, and it gives no result.